Mandate

Vinge advises Investor in connection with acquisition of shares in Mölnlycke Health Care

August 26, 2010

Vinge is advising Investor AB (publ) in connection with Investor’s agreement with Morgan Stanley Principal Investments to acquire Morgan Stanley’s 34 per cent equity stake in Mölnlycke Health Care Group AB. The purchase price amounts to EUR 510 million and following the transaction Investor will hold a 96 per cent equity stake. The remaining shares will be owned by Mölnlycke’s management and board.

Mölnlycke is a world leading manufacturer and provider of single-use surgical and wound care products and services, primarily for the professional healthcare sector. Investor together with Morgan Stanley originally invested in Mölnlycke in 2007.

Vinge’s team advising Investor consists of Ola Sandersson, Pontus Enquist, Dain Nevonen and Fredrik von der Esch. Johan Karlsson and Peter Alstegren are providing competiton law advice. Hans Wibom is the client relationship partner.

Related

Vinge advises Axcel and Sanviva on the acquisitions of DermaCura and YourRad

Vinge has advised Axcel Elevate I and Sanviva in connection with the acquisitions of DermaCura and YourRad.
September 07, 2026

Vinge advises Revivo Group on the acquisition of Premator

Revivo Group AB has acquired all the shares in Premator AB, the parent company of a group operating in the field of advanced surface treatment with extensive experience in shot blasting, anti-corrosion painting and related services. Operations are conducted in Sweden, Norway and Denmark.
September 03, 2026

Vinge advises the sellers on the sale of Nextory to Bonnier Books

Vinge has acted as legal adviser to the sellers in connection with Bonnier Books’ acquisition of Nextory, one of Europe’s leading streaming services for audiobooks and e-books. Bonnier Books is acquiring all shares in Nextory, and the transaction comprises Nextory’s operations in Sweden and internationally. The acquisition is a cash transaction and the parties have agreed not to disclose the purchase price. The transaction is subject to customary regulatory approvals.
September 02, 2026